Gold Gains 1%; CXApp Shares Spike Higher - AEON Biopharma (AMEX:AEON), Torrid Holdings (NYSE:CURV)

U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.3% on Monday.

The Dow traded down 0.67% to 39,538.91 while the NASDAQ fell 0.06% to 16,369.44. The S&P 500 also fell, dropping, 0.30% to 5,238.49.

Check This Out: Jim Cramer Likes Crown Castle, But Can't Recommend Archer Aviation: It Has 'No Earnings Power'

Communication services shares jumped by 1.3% on Monday.

In trading on Monday, real estate shares fell by 1.6%.

Torrid Holdings Inc. (NYSE:CURV) reported better-than-expected fourth-quarter financial results on Thursday.

CXApp Inc. (NASDAQ:CXAI) shares shot up 145% to $6.00 after the company announced a partnership with Google Cloud for acceleration of the CXAI platform.

Shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) got a boost, surging 72% to $0.1039 after the company FY23 operating results.

Doma Holdings Inc. (NYSE:DOMA) shares were also up, gaining 34% to $6.07 after the company entered a merger transaction with TRG to go private at $6.29 per share in cash.

Nuvve Holding Corp. (NASDAQ:NVVE) shares dropped 28% to $0.7897 after the company reported worse-than-expected fourth-quarter financial results.

Shares of AEON Biopharma, Inc. (NYSE:AEON) were down 41% to $6.83 after the company reported a fourth-quarter loss of 71 cents per share.

Disc Medicine, Inc. (NASDAQ:IRON) was down, falling 47% to $32.90 after the company reported topline results from the Phase 2 AURORA study of bitopertin in patients with EPP.

In commodity news, oil traded up 0.8% to $83.80 while gold traded up 1% at $2,261.30.

Silver traded up 0.8% to $25.12 on Monday, while copper rose 1.1% to $4.0505.

The ISM manufacturing PMI rose to 50.3 in March versus 47.8 in February and topping market estimates of 48.4.

U.S. construction spending fell by 0.3% from the prior month in February.

The S&P Global manufacturing PMI was revised lower to 51.9 in March compared to a preliminary reading of 52.5.

Now Read This: $5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.